Towards precision medicine in glioblastoma: the promise and the challenges. Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM. Neuro-Oncology. 2015, 17(8):1051-1063.
An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine. Nasser S, Kurdolgu AA, Izatt T, Aldrich J, Russell ML, Christoforides A, Tembe W, Keifer JA, Corneveaux JJ, Byron SA, Forman KM, Zuccaro C, Keats JJ, Lorusso PM, Carpten JD, Trent JM, Craig DW. Pacific Symposium on Biocomputing. 2015, 56-67.
Transcriptional profiling of GBM invasion genes identifies effective inhibitors of the LIM kinase-Cofilin pathway. Park JB, Agnihotri S, Golbourn B, Bertrand K, Luck A, Sabha N, Smith C, Byron S, Zadeh G, Croul S, Berens M, Rutka JT. Oncotarget. 2014, 5(19), 9382-9395.
The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Byron SA, Chen H, Wortmann A, Loch D, Gartside MG, Dehkhoda F, Blais SP, Neubert TA, Mohammadi M, Pollock PM. Neoplasia. 2013, 15(8), 975-88.
Negative regulation of NF-kB by the ING4 tumor suppressor in breast cancer. Byron SA, Min E, Thal TS, Hostetter G, Watanabe AT, Azorsa DO, Little TH, Tapia C, Kim S. PLoS One. 2012, 7(10).